Advertisement Pharmaceutical Business review - Page 225 of 5258 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 28, 2026

Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies

Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center on drug development for cardiometabolic diseases.

Insilico’s business model includes software solution licensing with 13 multinational pharma companies. Credit: metamorworks / Shutterstock.com.